Deciphera Pharmaceuticals (DCPH)
(Real Time Quote from BATS)
$25.52 USD
+0.02 (0.08%)
Updated May 24, 2024 03:56 PM ET
After-Market: $25.51 -0.01 (-0.04%) 4:14 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Deciphera Pharmaceuticals, Inc. [DCPH]
Reports for Purchase
Showing records 81 - 98 ( 98 total )
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
With QINLOCK 4L GIST Dominance, a Look Ahead to Value Drivers Beyond QINLOCK; Reit Buy and $80 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
QINLOCK Express, Making Station Stops in 4L GIST and Earlier Lines in the US and Beyond; Reit Buy and $80 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
QINLOCK Commercial Traction Indicates a Strong Launch Trajectory; Reit Buy and $80 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts Around Initial Market Uptake; Reit Buy and $80 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Looking Ahead to Multiple Value Drivers Beyond Ripretinib; Reit Buy and Raise PT to $80
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Transitioning Into a Commercial Stage Company With an Advancing Pipeline; Reit Buy and $60 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Deciphera Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Steady Pipeline Advancement With a Data-Rich Quarter; Reit Buy and $60 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A